Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Corvus Pharmaceuticals Inc(CRVS)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for CRVS
11/06/2026: CRVS (3-star) is currently NOT-A-BUY. Pass it for now.
Corvus Pharmaceuticals is a clinical-stage biotechnology company focused on developing oral, targeted immunotherapies for cancer and immune-mediated diseases. Its primary asset, soquelitinib, is a first-in-class ITK inhibitor currently showing promise in treating conditions like T-cell lymphoma and atopic dermatitis. The company's main strength lies in its experienced management and a strong cash runway that supports development through 2028. However, as a pre-commercial firm, Corvus faces significant execution and regulatory risks, with its valuation dependent on successful clinical trial outcomes. Investors should monitor upcoming Phase 3 data for soquelitinib and potential advancements in inflammatory indications, keeping in mind that this stock suits those comfortable with high clinical-stage volatility.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Corvus offers high-growth potential driven by clinical catalysts but lacks a proven commercial track record. |
| Momentum investor | Strong fit while signal remains positive | The stock often reacts significantly to positive clinical trial readouts and financing events. |
| Value investor | Weak fit | The company does not generate earnings and cannot be valued using traditional fundamental metrics. |
| Dividend investor | Weak fit | Corvus does not pay dividends and focuses all capital on pipeline development. |
| Low-risk investor | Weak fit | The company's clinical-stage nature and lack of commercial revenue present substantial risk of capital loss. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical trial results can cause significant swings in the stock price. |
| Valuation risk | High | As a pre-revenue company, current valuations are entirely speculative based on clinical success probability. |
| Competition risk (Biopharma landscape) | Medium / high | Corvus faces competition from larger, well-funded companies in the oncology and immunology space. |
| Business quality | Medium | The company has a strong, experienced management team but lacks a commercial-stage franchise. |
| Dividend income | Low / none | The company does not provide income to investors. |
| Execution risk | High | The primary risk is the failure to gain regulatory approval for soquelitinib or other candidates. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 381.25% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/06/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 889.08M USD | Price to earnings Ratio - | 1Y Target Price 31.5 |
Price to earnings Ratio - | 1Y Target Price 31.5 | ||
Volume (30-day avg) 1.1M shares | Beta 1.52 | 52 Weeks Range 6.39 - 26.95 | Updated Date 11/08/2026 |
52 Weeks Range 6.39 - 26.95 | Updated Date 11/08/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.72 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Development | Advancing proprietary drug candidates toward potential future regulatory approval and commercialization. | The company is currently an R&D operation and does not yet earn revenue from selling medicines. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 688.46M | Price to Sales(TTM) - |
Enterprise Value 688.46M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.36 | Shares Outstanding 84.35M | Shares Floating 72.99M |
Shares Outstanding 84.35M | Shares Floating 72.99M | ||
Percent Insiders 3.51 | Percent Institutions 86.87 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.